Clinical Trials
5 trialsNCT02257619 2026-04-21
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Phase 2 Terminated
NCT02917993 2026-02-09
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Phase 1/2 Completed
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT03425006 2023-09-13
Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
University of Pennsylvania
Phase 2 Terminated
NCT02355431 2019-03-08
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Incyte Corporation
Phase 2 Withdrawn